SPECIAL REPORT
Numerous head-to-head trials in multiple sclerosis have demonstrated the benefits of treatment with a higher-efficacy versus modest-efficacy disease-modifying therapy (DMT). Examples include the TRANSFORMS (fingolimod vs. interferon-b), CARE-MS (alemtuzumab vs. interferon-b), OPERA I/II (ocrelizumab vs. interferon-b), and ASCLEPIOS I/II (ofatumumab vs. teriflunomide) trials in relapsing MS. Read More
Two pioneers in MS nursing have joined the list of Canadian recipients of the Giants of MS award, presented by the Consortium of MS Centers (CMSC). Read More
Geography has a significant impact on MS patients’ access to care and treatment options, according to data presented at the Consortium of MS Centers (CMSC) 38th annual meeting, held May 29-June 1 in Nashville, Tennessee. Read More
An international panel of experts in conjunction with the Consortium of MS Centers (CMSC) has developed recommendations on the use of neurofilament-light chain (NfL) as a biomarker of disease activity in multiple sclerosis (Freedman et al. eBioMedicine 2024;101:104970). Read More